Amgen Presents New Lumakras® (Sotorasib) Plus Vectibix® (Panitumumab) Data in Patients With KRAS G12C-mutated Metastatic Colorectal Cancer

By /

Amgen announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS® in combination with Vectibix®.

Scroll to Top